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Background: In diagnostic pathology, HER2 status is determined in interphase nuclei by fluorescence in situ
hybridization (FISH) with probes for the HER2 gene and for the chromosome 17 centromere (CEP17). The latter
probe is used as a surrogate for chromosome 17 copies, however chromosome 17 (Chr17) is frequently rearranged.
The frequency and type of specific structural Chr17 alterations in breast cancer have been studied by using
comparative genomic hybridization and spectral karyotyping, but not fully detailed. Actually, balanced chromosome
rearrangements (e.g. translocations or inversions) and low frequency mosaicisms are assessable on metaphases
using G-banding karyotype and multicolor FISH (M-FISH) only.
Methods: We sought to elucidate the CEP17 and HER2 FISH patterns of interphase nuclei by evaluating Chr17
rearrangements in metaphases of 9 breast cancer cell lines and a primary culture from a triple negative breast
carcinoma by using G-banding, FISH and M-FISH.
Results: Thirty-nine rearranged chromosomes containing a portion of Chr17 were observed. Chromosomes 8 and 11
were the most frequent partners of Chr17 translocations. The lowest frequency of Chr17 abnormalities was observed in
the HER2-negative cell lines, while the highest was observed in the HER2-positive SKBR3 cells. The MDA-MB231 triple
negative cell line was the sole to show only non-altered copies of Chr17, while the SKBR3, MDA-MB361 and JIMT-1
HER2-positive cells carried no normal Chr17 copies. True polysomy was observed in MDA-MB231 as the only Chr17
alteration. In BT474 cells polysomy was associated to Chr17 structural alterations. By comparing M-FISH and FISH data,
in 8 out of 39 rearranged chromosomes only CEP17 signals were detectable, whereas in 14 rearranged chromosomes
HER2 and STARD3 genes were present without CEP17 signals. HER2 and STARD3 always co-localized on the same
chromosomes and were always co-amplified, whereas TOP2A also mapped to different derivatives and was co-amplified
with HER2 and STARD3 on SKBR3 cells only.
Conclusion: The high frequency of complex Chr17 abnormalities suggests that the interpretation of FISH results on
interphase nuclei using a dual probe assay to assess gene amplification should be performed “with caution”, given that
CEP17 signals are not always indicative of normal unaltered or rearranged copies of Chr17.
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Chromosome17 (Chr17) is the second most gene-dense
chromosome in the human genome [1], containing many
genes central to breast cancer development and progres-
sion, including oncogenes (HER2, TOP2A, STARD3, TAU),
tumor suppressor genes (TP53, BRCA1, HIC-1) and DNA
double-strand break repair genes (RDM1) [2-7]. In par-
ticular, the HER2 gene mapping to 17q11-q12 is amplified
in 15-20% of all breast cancers [8], it is a prognostic
marker for aggressiveness [8] and predicts the response to
anti-HER2 agents [8]. An accurate and definitive reporting
of HER2 status is thus essential for appropriate treatment
determination. Fluorescence in situ hybridization (FISH)
with dual probes for HER2 and for the Chr17 centromere
(CEP17) is the technique most frequently used in diag-
nostic pathology to determine the HER2 gene status in
interphase nuclei. The correction of HER2 gene copy
number using CEP17 signals is required to account for
Chr17 polysomy. However, by microarray-based com-
parative genomic hybridization (CGH) analysis we have
recently provided the first direct evidence that true
Chr17 polysomy is a rare event in breast cancer [9]. In-
deed, a number of CEP17 copies greater than 3 detected
by FISH analysis is frequently related to either a gain or
amplification of the centromere region, providing another
line of evidence that Chr17 usually displays very complex
rearrangements.
CGH, loss of heterozygosity (LOH), and molecular
genetics studies have shown that Chr17 is rearranged
in at least 30% of breast tumors [1,10,11] and presents
a number of rearrangement breakpoints mapping to
either its short or long arm. In particular, 17p is princi-
pally involved in losses, whereas CGH on 17q shows
complex combinations of overlapping gains and losses
[1,12]. In addition, CGH and spectral karyotyping (SKY)
studies have shown that Chr17 is one of the chromosomes
most frequently involved in translocations [13]. However
the frequency and type of specific structural Chr17 al-
terations in breast cancer have not been fully detailed.
For example, balanced chromosome rearrangements
(e.g. translocations or inversions) and low frequency
mosaicisms are assessable on metaphases using G-banding
karyotype and multicolor fluorescence in situ hybridization
(M-FISH) only.
The complexity of Chr17 rearrangements calls into
question the accuracy of HER2/CEP17 ratios evaluated
on interphase nuclei for diagnostic purposes. Indeed,
unsuspected Chr17 rearrangements may be contributing
to the equivocal results following in situ hybridization
testing, which account for about 10% of all IHC score
2+ carcinomas [14].
The aim of this study was to assess numerical alter-
ations and structural rearrangements of Chr17 in breast
cancer cells and to elucidate how these alterations mayimpact on the HER2/CEP17 FISH results on interphase
nuclei.
Methods
Cell lines
Nine established breast cancer cell lines [MCF7, T47D,
ZR-75-1 (estrogen receptor positive (ER+), HER2 not
amplified), BT474, MDA-MB361 (ER+, HER2 amplified),
SKBR3, JIMT-1 and KPL4 (ER-, HER2 amplified) and
MDA-MB231 (ER-, HER2 not amplified)] were obtained
from the American Type Culture Collection (ATCC,
Manassas, USA). The MCF7, T47D, ZR-75-1, SKBR3,
JIMT-1 and KPL4 cell lines were cultured in RPMI 1640
medium (Sigma, St. Louis, MO, USA), while the BT474,
MDA-MB231 and MDA-MB361 lines were cultured in
DMEM medium (Sigma). All culture media were sup-
plemented with 10% fetal bovine serum (FBS) (Sigma),
an antibiotic-antimycotic solution (1X) (Sigma) and L-
glutamine (2 mM) (Invitrogen GmbH, Karslruhe, Germany).
The cultures were maintained in an incubator at 37°C and
5% CO2.
Tumor samples for primary culture
The study on primary cultures was approved by the
ethics institutional review board for "Biobanking and
use of human tissue for experimental studies" of the
Pathology Units of the Azienda Ospedaliera Città della
Salute e della Scienza di Torino. At our Institution,
written informed consent is obtained from patients for
the use of residual tissues from the diagnostic procedures
in research studies.
We analyzed the cells of a triple negative breast car-
cinoma (TNBC) that metastasized to the peritoneum,
giving rise to a peritoneal effusion. The triple negative
phenotype was confirmed by immunohistochemistry
(IHC) for the estrogen receptor (ER) (Clone SP1, 1:50
diluted, Cell Marque, Rocklin, California), progester-
one receptor (PR) (Clone 1A6, 1:50 diluted, Leica Bio-
systems, Newcastle Upon Tyne, United Kingdom) and
by FISH for the HER2 gene on a cell block obtained
after centrifugation of an aliquot of the effusion. The
remaining part was used to set up a short-term primary
culture according to a protocol recently described [15].
The epithelial origin of the cells was confirmed by the
positive expression of cytokeratins (clones AE1/AE3
and PCK26, pre-diluted, Ventana-Diapath, Tucson, AZ,
USA) and by the absence of the mesothelial marker calre-
tinin (polyclonal; 1:100 diluted, Invitrogen) using an im-
munohistochemical procedure on cells grown directly on
sterilized slides [15].
G-Banding and karyotyping
Metaphases for performing conventional and molecular
cytogenetic analysis (M-FISH and FISH) were obtained
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described [16].
Metaphases image acquisition and subsequent karyotyp-
ing were performed by using a Nikon microscope with the
cytogenetic software CytoVision System (Applied Imaging,
Santa Clara, CA). Between 10 and 26 metaphase cells with
good dispersion and morphology were analyzed for each
cell line. Chromosome aberrations were described accord-
ing to the International System for Human Cytogenetic
Nomenclature 2013 (ISCN) [17].
Multi-color fluorescence in situ hybridization (M-FISH)
M-FISH was performed as recently described [16]. Briefly,
we used a probe cocktail containing 24 differentially
labeled chromosome-specific painting probes (24xCyte
kit MetaSystems, Altlussheim, Germany) that was de-
natured and hybridized to denatured tumor metaphase
chromosomes. The slides were incubated at 70°C in
saline solution (2xSSC), denatured in NaOH, dehydrated
in an ethanol series, air-dried, covered with 10 μl of the
probe cocktail (denatured) and finally hybridized for two
days at 37°C. Subsequently, the slides were washed with
post-hybridization buffers, dehydrated in an ethanol series
and counter-stained with 10 μl of DAPI/antifade. The
Metafer system and the Metasytems ISIS software (Carl
Zeiss, Metasystems, GmbH) were used for signal detection
and metaphase analysis. At least 10 metaphases exhibitingTable 1 Aberrations of Chr17 as revealed by G-Banding, M-FI
culture raised from a triple negative breast carcinoma
Cell lines Type of rearrangement
MCF7 (ER+/HER2-) der(6)t(6;17;16)(q25;q21;?)[100
T47D (ER+/HER2-) dic(9;17)t(9;17)(p12;p13)[100]
ZR-75-1 (ER+/HER2-) der(11)t(11;17)(p15;q?21)[100]
BT474 (ER+/HER2+) der(X)t(X;17)(q13;q11q12)del(X
(p15;q11q12)x2[100],der(11)t(1
(?;q?11.2)hsr(17)(q11q12)x2[57
der(17)t(6;17)(?;p13)t(15;17)(q1
MDA-MB361 (ER+/HER2+) der(8)t(8;17)(p21;q11q12)t(5;17
[100],der(17)t(6;17)(?;q21)[100],d
[100], der(17)t(17;21)(q21;q22)[
SKBR3 (ER-/HER2+) der(X)t(X;17)(q21;q?21)hsr(17)(
[100],der(17)t(8;17)(?;q25)dup(
[42],der(17)t(3;8;13;17;17;20)(?;?
JIMT-1 (ER-/HER2+) der(3)t(3;12)(p21;?)t(2;3)(?;q12)
(q11.1;q12)hsr(17)(q11q12)[10
(18)t(17;18)(q12;q21)t(16;17)(q
KPL4 (ER-/HER2+) der(1)t(1;17)(p36.3;q11q12)hsr
(p24;q11q12)t(13;17)(p11.2;q1
MDA-MB231 (ER-/HER2-) //
TNBC CASE (ER-/HER2-) der(17)t(8;17)(q21;p12)[100],de
t(17;19)(p11.1;?)[15],der(17)t(17
The % of cells for which each abnormality was observed is indicated at the end of
chromosome count was 26 for MCF7 cells; 24 for T47D cells; 10 for ZR-75-1 cells an
15 for KPL4 cells, 14 for MDA-MB231 cells and 13 for the triple negative breast cancthe same derivative chromosomes were studied for each
cell line.
FISH for the HER2, STARD3 and TOP2A genes
FISH experiments were performed to define the HER2,
STARD3 (17q12) and TOP2A (17q21-q22) gene status
and mapping. In HER2 amplified tumors STARD3 is in-
cluded in the smallest region of amplification (SRA) in-
volving HER2, whereas TOP2A is reported to pertain
to a separate amplicon.
Two commercial dual-color probes for HER2 (Spec-
trumOrange)/CEP17 (SpectrumGreen) and TOP2A (Spec-
trumOrange)/CEP17 (SpectrumGreen) (all from Abbott
Molecular, Downers Grove, IL, USA) were used separately
on each cell line.
For the STARD3 gene, FISH studies were performed
using both an alpha satellite probe specific for Chr17
(CEP17) that was directly labeled with a green fluoro-
chrome (Abbott molecular) and a STARD3 specific locus
probe fosmid WI2-2398I17 (17q12) that was made in-
house. The clone was obtained from BACPAC Resources
Center (Children’s Hospital Oakland Research Institute,
CA, USA). The UCSC database (http://genome.ucsc.edu,
February 2009 release) was queried to localize the probe.
The fosmid was expanded, extracted using the QIAGEN
Plasmid Purification Kit (QiagenGmbH, Hilden, Germany)
and then directly labeled with SpectrumOrange-dUTPSH and FISH in nine breast cancer cell lines and a primary
],der(17)t(8;17)t(1;8)[100],der(17)t(17;19)(p11.1;p12)[65]
,der(11)t(11;17)(p15;q?21)t(11;17)(?;q25)[88],der(17)t(6;17)(p12;p11.2)[100]
)(p21)hsr(17)(q11q12)x2[39],der(11)t(8;17)(q21.1;q11q12)t(11;17)
1;17)(q?14;q?11.2)hsr(17)(q11q12)[39],der(11)t(11;17)(q?14;?)t(8;17)
],der(13)t(13;17)(q10;q11q12)t(13;17)(q10;q11q12)hsr(17)(q11q12)x2[87],
1.2;q25)hsr(17)(q11q12)x2[96]
)(?;q11q12)hsr(17)(q11q12)[100],der(8)t(8;17)(p21;q25)t(8;17)(q13;q11.2)
er(17)t(7;17)(?;p13)[100], der(17)t(17;20)(p11.1;?)t(9;20)(?;q13.1)t(5;9)(q14;?)
100]
q11q12)x2[79], der(17)t(8;17)(q12;?)dup(17)(?)hsr(17)(q11q12)hsr(17)(q21)
17)(q22q25)[37],der(17)t(8;13;14;17;21)(?;q?;q?;q11q12;?)hsr(17)(q11q21)
;q12;q12;?p;?)[74], der(17;17)t(17;17)(q25;?)dup(17)(q22q25)t(17;20)(?;?)[100]
t(2;17)(?;q11q12)hsr(17)(q11q12)[100], ,der(8)t(8;17)(q13;q11q12)t(8;17)
0],der(17)t(8;17)(?;p13)[67],der(17)t(17;22)(p13;?)t(17;22)(q11.1;?)[100],der
23;q12)[100]
(17)(q11q12)[100],der(6)t(6;17)(p12;q11.2)t(8;17)(q25;?)[93],der(9;13)t(9;17)
1.2)hsr(17)(q11q12)[100], der(17)t(3;17)(q13;q11)t(6;17)(?;q11)[66.6]
r(17)t(16;17)(q11.2;q11.1)[15],der(17)del(17)(p11.2)del(17)(q11.2)[69],der(17)
;22)(p11.1;q11.2)[62]
each abnormality within square brackets. The number of cells examined for
d for BT474 cells; 10 for MDA-MB361 cells; 19 for SKBR3 cell; 18 for JIMT-1 cells;
er case (TNBC).
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(Abbott Molecular) according to the manufacturer’s
instructions. The fosmid clone was tested on meta-
phase and interphase cells of healthy donors, obtained
using conventional cytogenetic methods, to analyze the
position and strength of the signal, the presence/absence of
background and cross-hybridization and the hybridization
efficiency.
FISH with the HER2/CEP17, STARD3/CEP17 and
TOP2A/CEP17 probes was performed separately on
each cell line on fresh slides from methanol and acetic
acid fixed cells according to the manufacturers’ instruc-
tions. Briefly, the slides were washed at 37°C in 2x saline-
sodium citrate buffer (SSC), dehydrated in an ethanol
series, air-dried, covered with 10 μl of probe, co-denatured
in HYBrite System at 70°C for 5 min and hybridized
overnight at 37°C. Slides were then washed with a
post-hybridization buffer (2xSSC/0.3% Nonidet P-40),
dehydrated in an ethanol series and counter-stainedFigure 1 Analysis of Chr17 using G-Banding, dual-color FISH (HER2/CE
T47D, ZR-75-1 and MDA-MB231 not HER2 amplified breast cancer cel
visualized by G-Banding technique on the left and by M-FISH on the right. Fo
partners are numbered on the right hand side of the chromosomes and the
brackets at the end of each abnormality. CEP17, HER2, STARD3 and TOP2A are
TOP2A/CEP17, respectively) whenever mapped to the corresponding derivativ
are red-labeled).with 10 μl DAPI/antifade. Metaphases and nuclei were
selected with an AxioImager Z1 epifluorescence micro-
scope (Carl Zeiss, Germany). Analysis of the signal pattern
on the interphase nuclei and metaphases was performed
with the ISIS software. The number of FISH signals and
the localization of the signals were analyzed in at least 10
metaphases and interphase nuclei.
Results
Structural alterations of Chr17
The specific Chr17 alterations we found are detailed in
Table 1. In 8 out of the 9 cell lines analyzed we identified
39 rearranged chromosomes containing a portion of Chr17
(mainly its long arm) (Figures 1, 2, 3 and 4). The triple
negative MDA-MB231 cells showed no Chr17 alterations,
while the HER2 amplified MDA-MB361, SKBR3 and
JIMT-1 cell lines carried no normal copies of Chr17. In
particular, the SKBR3 cells harbored 10 different types
of structural abnormalities on Chr17, making it the cellP17, STARD3/CEP17 and TOP2A/CEP17) and M-FISH in the MCF7,
l lines. Rearranged chromosomes containing a portion of Chr17 are
r M-FISH the classified color of Chr17 is shown in pink, the translocation
frequency at which each abnormality was observed is indicated in
shown in the middle by dual-color FISH (HER2/CEP17, STARD3/CEP17,
es (CEP17 is green-labeled; HER2, STARD3 and TOP2A genes
Figure 2 Analysis of Chr17 using G-Banding, dual-color FISH (HER2/CEP17, STARD3/CEP17 and TOP2A/CEP17) and M-FISH in KPL4 HER2
amplified breast cancer cell line showing four translocated Chr17 in addition to the normal-appearing copies of Chr17 and in one
triple negative breast cancer case (TNBC) showing five rearranged copies of Chr17. Rearranged chromosomes containing a portion of
Chr17 are visualized by G-Banding technique on the left and by M-FISH on the right. For M-FISH the classified color of Chr17 is shown in pink,
the translocation partners are numbered on the right hand side of the chromosomes and the frequency at which each abnormality was observed
is indicated in brackets at the end of each abnormality. CEP17, HER2, STARD3 and TOP2A are shown in the middle by dual-color FISH (HER2/CEP17,
STARD3/CEP17, TOP2A/CEP17, respectively) whenever mapped to the corresponding derivatives (CEP17 is green-labeled; HER2, STARD3 and TOP2A
genes are red-labeled). In the TNBC cells the chromosome in which we identified Chr17 material only is a der(17)del(17)(p11.2)del(17)(q11.2) with
a deletion on both short and long arm involving 17q12-q21.
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ities. The lowest frequency of Chr17 abnormalities was
observed in HER2 negative cells, which carried between
2 and 3 different types of alterations.
We defined nine regions of Chr17 frequently involved
in the observed structural alterations: 17p11, 17p13,
17q11.2, 17q11-12, 17q12, 17q21, 17q22, 17q23 and
17q25. The 17q11-12 region was the most frequent long
arm portion involved in structural alterations. This
region was affected in the BT474, MDA-MB361, SKBR3,
JIMT-1 and KPL4 HER2 amplified cell lines, while
17p11 and 17p13 were commonly affected in the MCF7,
ZR-75-1, MDA-MB361 and the SKBR3 and in T47D,
MDA-MB361, JIMT-1 cells, respectively (Table 1).Using G-Banding, numerous complex derivative chro-
mosomes containing material from Chr17 were observed
in all cell lines except for MDA-MB231. Some of the de-
rivative chromosomes were present in duplicate (Table 1).
Chr17 deletions and dicentric chromosomes were ob-
served only in the T47D and SKBR3 cells.
M-FISH demonstrated that chromosome 8 and chromo-
some 11 were the most frequent translocation partners of
Chr17 (Table 2). Twelve different rearrangements between
Chr17 and chromosome 8, involving mainly their long arms
(8q11.1, 8q12, 8q13, 8q21 and 8q24) were identified in
MCF7, MDA-MB361, BT474, SKBR3 and JIMT-1 cells.
Similarly, 5 translocations between Chr17 (long arm) and
chromosome 11 (involving 11p15, 11q13 and 11q23) were
Figure 3 Analysis of Chr17 using G-Banding, dual-color FISH (HER2/CEP17, STARD3/CEP17 and TOP2A/CEP17) and M-FISH in BT474 and
MDA-MB361 HER2 amplified breast cancer cell lines showing six translocated copies of Chr17. Rearranged chromosomes containing a
portion of Chr17 are visualized by G-Banding technique on the left and by M-FISH on the right. For M-FISH the classified color of Chr17 is shown
in pink, the translocation partners are numbered on the right hand side of the chromosomes and the frequency at which each abnormality was
observed is indicated in brackets at the end of each abnormality. CEP17, HER2, STARD3 and TOP2A are shown in the middle by dual-color FISH
(HER2/CEP17, STARD3/CEP17, TOP2A/CEP17, respectively) whenever mapped to the corresponding derivatives (CEP17 is green-labeled; HER2,
STARD3 and TOP2A genes are red-labeled).
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chromosome 6 were observed in five cell lines, and translo-
cations between Chr17 and chromosomes X, 1, 3, 7 and 16
were observed only in HER2 positive cells (Table 2). We
identified 5 different alterations of Chr17 in the primary
TNBC culture, involving both the short (17p11.1, 17p11.2,
17p12) and the long (17q11.1 and 17q11.2) arms. In
addition, numerous complex Chr17 derivatives containing
material from chromosomes 8, 16, 19 and 22 were observed.
Mapping CEP17 and the 17q12–q21 amplicon
We considered the chromosomal correlation of HER2,
STARD3 and TOP2A genes mapping to 17q12–q21 with
CEP17 as shown by FISH on metaphase chromosomes
and we compared the results to the interphase pattern. By
M-FISH we reported the specific rearrangements. Out ofthe 39 rearranged chromosomes containing a portion of
Chr17 identified by M-FISH, 12 harbored HER2, STARD3
(which mapped always together) and TOP2A; 16 harbored
HER2 and STARD3, 1 harbored only TOP2A, 2 did not
show either CEP17, HER2, STARD3 or TOP2A signals.
Notably, 8 of the 39 rearranged chromosomes carried
CEP17 signals without HER2 and STARD3 signals and
14 harbored HER2 and STARD3 genes but not CEP17.
The specific patterns observed by FISH in each cell
line are reported below.
Triple negative cell lines
In the MDA-MB231 triple negative cells the FISH (both
in interphase and metaphase) and M-FISH patterns
corresponded to three copies of normal Chr17, each
with one CEP17 green signal and one red signal
Figure 4 Analysis of Chr17 using G-Banding, dual-color FISH (HER2/CEP17, STARD3/CEP17 and TOP2A/CEP17) and M-FISH in SKBR3 and
JIMT-1 HER2 amplified breast cancer cell lines showing four or six translocated copies of Chr17. Rearranged chromosomes containing a portion
of Chr17 are visualized by G-Banding technique on the left and by M-FISH on the right. For M-FISH the classified color of Chr17 is shown in pink, the
translocation partners are numbered on the right hand side of the chromosomes and the frequency at which each abnormality was observed is indicated
in brackets at the end of each abnormality. CEP17, HER2, STARD3 and TOP2A are shown in the middle by dual-color FISH (HER2/CEP17, STARD3/CEP17,
TOP2A/CEP17, respectively) whenever mapped to the corresponding derivatives (CEP17 is green-labeled; HER2, STARD3 and TOP2A genes are red-labeled).
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(Table 3, Figures 5 and 1).
The TNBC primary culture nuclei displayed the same
FISH pattern for the HER2, STARD3, TOP2A genes and
CEP17. Four green CEP17 signals and two red signals
were observed (Figures 5 and 2). Two red and two green
signals corresponded to two Chr17 derivatives, namely
der(17)t(8;17)(q21;p12)x2 (100%), while the other two
green signals (without the HER2, STARD3 and TOP2A
genes) mapped to der(17)t(17;22)(p11.1;q11.2) (62%)
and der(17)del(17)(p11.2)del(17)(q11.2) (69%). This last
Chr17 derivative showed deletion on both short and long
arms involving the 17q12-21 region (Figure 2).
ER+/HER2 not amplified cell lines
In T47D and ZR-75-1 interphase nuclei, the same copy
numbers of HER2, STARD3 and TOP2A genes and ofCEP17 were observed (Table 3, Figure 5). Four copies
were observed in the T47D nuclei and three in the
ZR-75-1 nuclei (Table 3, Figure 5).
The T47D cells showed two normal Chr17 and two
Chr17 derivatives carrying both CEP17 and the three
genes (Figures 5 and 1). M-FISH showed that the de-
rivative chromosome previously reported as der(9)t(9;17)
(p13;q11) [18] was a dic(9;17)t(9;17)(p12;p13) (Figure 1).
In ZR-75-1, M-FISH showed that HER2, STARD3 and
TOP2A genes mapped to two normal Chr17 and one de-
rivative Chr17 (Table 3, Figures 5 and 1).
MCF7 interphase nuclei displayed four CEP17 green
signals and two red signals for the HER2 and STARD3
genes (Table 3, Figure 6). This pattern corresponded to
one CEP17 signal and one copy of the HER2 and STARD3
genes located on two normal Chr17 and two CEP17 sig-
nals on two Chr17 derivatives as confirmed by M-FISH
Table 2 Frequency of translocation partners of Chr17 in nine breast cancer cell lines
Translocation partner Chromosomal
abnormality
Number of
abnormalities
No of cell
lines
Cell lines
Chromosome 8 der 12 5 MCF7, MDA-MB361, SKBR3, JIMT-1, BT474
Chromosome 11 der 5 2 ZR-75-1, BT474
Chromosome 6 der 5 5 MCF7, ZR-75-1, MDA-MB361, BT474, KPL4
Chromosome X der 2 2 BT474, SKBR3
Chromosome 9 der 2 2 KPL4, T47D
Chromosome 9 dic 1 1 T47D
Chromosome 3 der 2 2 JIMT-1, KPL4
Chromosome 7 der 1 1 MDA-MB361
Chromosome 13 der 2 2 BT474, KPL4
Chromosome 1 der 1 1 KPL4
Chromosome 16 der 1 1 JIMT-1
Chromosome 17 der 1 1 SKBR3
Chromosome 19 der 1 1 MCF7
Chromosome 20 der 1 1 MDA-MB361
Chromosome 21 der 1 1 MDA-MB361
Chromosome 22 der 1 1 JIMT-1
der = derivative chromosome; dic = dicentric chromosome.
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http://www.biomedcentral.com/1471-2407/14/922(Figure 1). The FISH pattern for TOP2A was similar to
that observed for the HER2 and STARD3 genes, with
the only exception of having an additional TOP2A copy
mapping on a derivative chromosome 6 (Figures 6
and 1).
HER2 amplified cell lines
HER2, TOP2A and STARD3 gene amplifications were
found within chromosomes as homogeneously staining
regions (HSRs) but not in extra-chromosomal, double-
minute chromosomes (DMs). All of these cell lines showed
HER2 and STARD3 co-amplification.
In BT474 interphase nuclei, six CEP17 signals and sev-
eral clusters of HER2 and STARD3 were observed. This
pattern corresponded to nine clusters and six individual
red signals in metaphases (Figure 6). By comparing FISH
and M-FISH data, we showed that four CEP17 and four
red signals were located on four normal copies of Chr17,
and two CEP17 signals and two clusters of red signals
on two Chr17 derivatives as shown by M-FISH: der(17)t
(6;17)(?;p13)t(15;17)(q11.2;q25)hsr(17)(q11q12)x2 (96%).
The remaining seven clusters of red signals mapped to
five previously unreported highly rearranged chromosomes
(Table 3, Figure 3).
BT474 cells showed normal TOP2A gene copy num-
bers, and four red signals were observed on four normal
copies of Chr17 only (Figures 6 and 3).
In the MDA-MB361 nuclei four CEP17 signals, one
red cluster and four individual red signals (HER2 and
STARD3) were observed (Figure 6). None of these greenand red signals were located on normal copies of Chr17
(Table 3, Figure 3). Three individual red signals were
correlated with the centromeric locus and located on
three Chr17 derivatives. The other individual red signal
mapped to a chromosome 8 derivative and the only red
cluster, indicative of HER2 and STARD3 amplification,
was located on another chromosome 8 derivative. The
remaining CEP17 signals, without red signal (HER2 and
STARD3 deletion), mapped to a complex translocation
of Chr17 involving chromosomes 5, 9 and 20 (Figure 3).
These cells harbored a TOP2A deletion, as four chro-
mosomes with CEP17 were identified, but only one of
them had a TOP2A signal (Figures 6 and 3).
In the SKBR3 cells, HER2 and STARD3 co-amplification
was observed in 100% of metaphase and interphase nuclei
analyzed. Seven CEP17 signals and sixteen clusters and
four individual red signals (HER2 and STARD3) were ob-
served on numerous highly rearranged chromosomes
(Table 3 and Figure 6). In particular, two CEP17 and one
red signal mapped to the dicentric Chr17, der(17;17)t
(17;17)(q25;?)dup(17)(q22q25)t(17;20)(?;?) (100%), which
had not been previously reported (Figure 4). In two Chr17
derivatives TOP2A was co-amplified with HER2 either as a
single amplicon (der(17)t(8;13;14;17;21)(?;q?;q?;q11q12;?)
hsr(17)(q11q21)) or as separate amplicons (der(17)t(8;17)
(q12;?)dup(17)(?)hsr(17)(q11q12)hsr(17)(q21)) (Figure 4).
In addition, TOP2A deletion was detected on der(X)t
(X;17)(q21;q?21)hsr(17)(q11q12). In the remaining deriva-
tive chromosomes without gene amplification, TOP2A
showed the same FISH pattern observed for HER2, in
Table 3 HER2 and STARD3 FISH pattern and complex Chr17 rearrangements in nine breast cancer cell lines and one
primary culture raised from a triple negative breast carcinoma
Cell line CEP 17 signals
(green)
HER2 signals (red) Chr17 Complex abnormalities encompassing
HER2 AmplificationCluster Individual Normal Derivatives
MCF7 4 0 2 2* der(17)t(8;17)t(1;8)
der(17)t(17;19)(p11.1;p12)
T47D 4 0 4 2* dic(9;17)(p12;p13)*x2
ZR-75-1 3 0 3 2* der(17)t(6;17)(p12;p11.2)*
BT474 6 9 6 4* der(17)t(6;17)(?;p13)t(15;17)
(q11.2;q25)hsr(17)(q11q12**)x2
der(X)t(X;17)(q13;q11q12)del(X)(p21)hsr
(17)(q11q12**)x2
der(11)t(8;17)(q21.1;q11q12*)t(11;17)
(p15;q11q12)x2
der(11)t(11;17)(q?14;q?11.2)hsr(17)(q11q12**)
der(11)t(11;17)(q?14;?)t(8;17)(?;q?11.2)hsr(17)
(q11q12**)x2
der(13)t(13;17)(q10;q11q12)t(13;17)(q10;q11q12)
hsr(17)(q11q12**)x2
der(17)t(6;17)(?;p13)t(15;17)(q11.2;q25)hsr(17)
(q11q12**)x2
MDA-MB361 4 1 4 0 der(17)t(6;17)(?;q21)* der(8)t(8;17)(p21;q11q12)t(5;17)(?;q11q12)hsr(17)
(q11q12**)
der(17)t(7;17)(?;p13)* der(8)t(8;17)(p21;q25)t(8;17)(q13;q11.2*)
der(17)t(17;20)(p11.1;?)t(9;20)
(?;q13.1)t(5;9)(q14;?)
der(17)t(17;21)(q21;q22)*
SKBR3 7 16 4 0 der(17)t(8;17)(q12;?)dup(17)(?)
hsr(17)(q11q12**/**/**/**/**/**)
hsr(17)(q21)x2
der(X)t(X;17)(q21;q?21)hsr(17)(q11q12**)x2
der(17)t(8;17)(?;q25)dup(17)
(q22q25)*
der(17)t(8;17)(q12;?)dup(17)(?)hsr(17)(q11q
12**/**/**/**/**/**)hsr(17)(q21)x2
der(17)t(8;13;14;17;21)(?;q?;q?;
q11q12;?) hsr(17)(q11q21**/**)
der(17)t(8;13;14;17;21)(?;q?;q?;q11q12;?)hsr(17)
(q11q21**/**)
der(17)t(3;8;13;17;17;20)(?;?;q12*;
q12*;?p;?)
der(17;17)t(17;17)(q25;?)dup(17)
(q22q25)t(17;20)(?;?)*
JIMT-1 2 2 2 0 der(17)t(8;17)(?;p13)* der(3)t(3;12)(p21;?)t(2;3)(?;q12)t(2;17)(?;q11q12)
hsr(17)(q11q12**)
der(17)t(17;22)(p13;?)t(17;22)
(q11.1;?)
der(8)t(8;17)(q13;q11q12)t(8;17)(q11.1;q12)hsr
(17)(q11q12**)
KPL4 3 2 3 2* der(6)t(6;17)(p12;q11.2*)t(8;17)
(q25;?)
der(1)t(1;17)(p36.3;q11q12)hsr(17)(q11q12**)
der(17)t(3;17)(q13;q11)t(6;17)
(?;q11)
der(9;13)t(9;17)(p24;q11q12)t(13;17)(p11.2;q11.2)
hsr(17)(q11q12**)
MDA-MB231 3 0 3 3* 0 0
TNBC CASE 4 0 2 0 der(17)t(8;17)(q21;p12)*x2
der(17)del(17)(p11.2)del(17)
(q11.2)
der(17)t(17;22)(p11.1;q11.2)
*Indicates the presence of one red signal (HER2) on a normal Chr17 or on a derivative Chr17.
**Indicates the presence of one red cluster (HER2) on a derivative Chr17.
**/**Indicates the presence of two red clusters (HER2) on a derivative Chr17.
**/**/**/**/**/**Indicates the presence of six red clusters (HER2) on a derivative Chr17.
Scoring of interphase nuclei to obtain the final result on HER2 gene status performed based both on a dual-FISH and a single FISH assay (according o the new
ASCO/CAP guidelines [19]) showed no differences in the final result for each of the cell lines.
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Figure 5 Representative FISH images of the MDA-MB231, T47D and ZR-75-1 breast cancer cells and one TNBC case using HER2/CEP17,
STARD3/CEP17 and TOP2A/CEP17 dual-color probes. Metaphase spreads are shown and boxes indicate representative interphase nuclei for
each case. None of these cell lines showed amplification of the HER2, STARD3 or TOP2A genes. Gene signals are red-labeled, CEP17 signals
are green-labeled.
Rondón-Lagos et al. BMC Cancer 2014, 14:922 Page 10 of 14
http://www.biomedcentral.com/1471-2407/14/922which all distinct HER2 genes were accompanied by
distinct TOP2A genes (Figures 4 and 6).
In the JIMT-1 cells, two CEP 17 signals and two clus-
ters and two individual red signals were observed for
HER2 and STARD3 genes (Figure 7). The two clusters of
red signals mapped to two chromosomes lacking CEP17
(Table 3 and Figure 4). One of the two individual red
signals was observed on a Chr17 derivative while the
other was on a chromosome 18 derivative (Table 3 and
Figure 4). We also observed HER2 and STARD3 deletion
on der(17)t(17;22)(p13;?)t(17;22)(q11.1;?) (Figure 4).
TOP2A was not amplified and the FISH pattern showed
two red and two CEP17 signals: one red signal mapped to
a Chr17 derivative, while the other mapped to a chromo-
some 18 derivative. In addition, a loss of the TOP2A gene
(TOP2A deletion) was observed on der(17)t(17;22)(p13;?)t
(17;22)(q11.1;?), similar to that observed for the HER2 andSTARD3 genes (Figure 4). TOP2A signals were not ob-
served on derivative chromosomes with HER2 amplifica-
tion (Figure 4).
The KPL4 cells showed three CEP17 signals and two
clusters and three individual red signals of HER2 and
STARD3 genes (Figure 7). Two CEP17 and two red signals
were located on two normal copies of Chr17, the other
green and red individual signals corresponded to complex
rearrangements involving Chr17 (Table 3, Figure 2). Like
the JIMT-1 cells, the HER2 and STARD3 gene clusters
were located on highly rearranged chromosomes (Table 3,
Figure 2).
These cells did not show TOP2A gene amplification
(Figure 7). Instead, one CEP17 signal and one red signal
were observed each on two distinct normal Chr17 copies,
and one red signal mapped to a chromosome 6 derivative
(Figure 2).
Figure 6 Representative FISH images of the MCF7, BT474, MDA-MB361 and SKBR3 breast cancer cell lines using HER2/CEP17, STARD3/
CEP17 and TOP2A/CEP17 dual-color probes. Metaphase spreads are shown and boxes indicate representative interphase nuclei for each case.
FISH images for the BT474, MDA-MB361 and SKBR3 cells demonstrated HER2 and STARD3 gene amplification, while TOP2A gene amplification was
observed in the SKBR3 cells only. Gene signals are red-labeled, CEP17 signals are green-labeled.
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By comparing the HER2/CEP17 FISH pattern in meta-
phase versus interphase nuclei, the present study dem-
onstrated that a CEP17 signal rarely corresponds to a
single intact Chr17, in both HER2+ and HER2- cell
lines. It is well known that cells of long-term cultures
may show high chromosomal rearrangements, however
Chr17 was altered even in the short-term TNBC primary
culture. Although obtained in a single primary cell line
this specific finding may corroborate our hypothesis that
chromosomal alterations involving Chr17 in breast cancer
may be indeed very complex and merit further investiga-
tion in primary cell cultures obtained from carcinomas of
different phenotypes.
This extensive cytogenetic analysis of Chr17 demon-
strated that only the MDA-MB231 triple negative showed
true polysomy (normal chromosome acquisition) as theonly Chr17 alteration. The BT474 HER2-positive cells
showed Chr17 polysomy together with different Chr17
rearrangements. In ER+/HER2 not amplified cell lines
normal copies of Chr17 coexist with rearranged Chr17
copies that either harbor or do not harbor the HER2
gene. On the other hand, some of the HER2 amplified
cell lines did not show any normal copies of Chr17 and
the HER2-STARD3 gene clusters were observed as HSR
on complex rearranged chromosomes. In addition, the
Chr17 derivatives (carrying CEP17) did not always show
HER2 gene clusters, and these latter were not exclusively
observed in Chr17 derivatives. In particular, in the BT474
cells 7 of 9 HER2 gene clusters were found on derivatives
lacking CEP17.
In breast cancer specimens the analysis of the HER2
gene in interphase nuclei is requested after an equivocal
immunohistochemical result (score 2+) of HER2 expression
Figure 7 Representative FISH images of the JIMT-1 and KPL4 breast cancer cell lines using HER2/CEP17, STARD3/CEP17 and TOP2A/
CEP17 dual-color probes. Metaphase spreads are shown and boxes indicate representative interphase nuclei for each case. FISH images for the
JIMT-1 and KPL4 cells demonstrate HER2 and STARD3 gene amplification, while TOP2A gene amplification was not observed in these cells. Gene
signals are red-labeled, CEP17 signals are green-labeled.
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single-signal (HER2 probe) assays may be performed
assessing the HER2/CEP17 ratio or the absolute HER2
copy number, respectively. In the case of the double-signal
assay, the recent ASCO/CAP guidelines [19] recommend
using the HER2/CEP17 ratio to screen for amplified or
not amplified breast cancers. However, our data provide
another line of evidence that the interpretation of the re-
sults of the ISH analyses on interphase nuclei using a
dual-signal assay should be performed “with caution”,
given the high frequency of complex Chr17 abnormalities
involving both CEP17 and HER2 loci. This has to be taken
particularly into account in cases showing an increased
number of discrete HER2 signals, in which the HER2/
CEP17 ratio may highly impact on the final definition of
the gene status, in contrast with cases with HER2 gene
clusters of amplification. The introduction by the ASCO/
CAP 2013 of an algorithm that takes into account the ra-
tio first and then the HER2 gene copy numbers represents
an improvement in the identification of HER2 positive tu-
mors by dual-signal assays. We should point out that the
sole HER2 gene copy number method, as used in single-
signal assay, best identifies HER2 gene amplification in
interphase nuclei, as CEP17 copy numbers do not reflect
Chr17 copy numbers. This finding should be taken par-
ticularly into account for those scenarios in which mono-
somy of Chr17 may be encountered. In this respect the
new guidelines seem to be controversial depending on the
method of ISH analysis employed. Indeed, by following
the single signal copy number method cases with low copy
number (<4) are labeled as negative, while the same
tumors showing monosomy of Chr17 are labeled aspositive if the HER2/CEP17 ratio is employed [19-21].
Although on one side the HER2/CEP17 ratio may still lead
to issues when interpreting Chr17 monosomy and HER2
copy numbers would be more reliable, on the other hand
we should also acknowledge that double signal assays with
CEP17 counts may still provide informative parameters.
Interestingly, a recent study on patients treated with
anthracycline-based chemotherapy in the neoadjuvant set-
ting has shown that CEP17 duplication strongly correlated
with higher pCR rates [22] than did TOP2A and HER2, in
both univariable and multivariable analyses. This shows
that alteration of CEP17 copy number detectable in inter-
phase nuclei may still represent a prognostic or predictive
indicator, although we cannot decipher the real complex-
ity of the rearrangements this chromosome undergoes to.
For instance, Chr17 was frequently translocated with
chromosome 8 and 11. These chromosomes have been
observed in translocations in many breast cancer cell
lines [13,23] and have also been shown to participate
in translocation events in cases of primary breast car-
cinomas [24]. Cytogenetic analysis of primary cultures
would be of invaluable help in understanding whether
such alterations recapitulate those of primary tumors.
In the primary culture here analyzed, chromosome 8
was involved in one of the translocations.
Another finding of our analyses is the invariable co-
amplification of HER2 and STARD3 on the same meta-
phase chromosomes. Increased co-amplification of HER2
and STARD3 has been described to be correlated with ac-
quired lapatinib resistance [23]. On the other hand, the
simultaneous amplification of HER2 and TOP2A was only
found in SKBR3 cells, where a pattern of amplification
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derivatives. This observation provides another line of
evidence that, despite the genomic proximity of HER2
and TOP2A and the observation that TOP2A amplifica-
tion seems to be restricted to tumors harboring HER2
amplification, these two genes are likely to pertain to
separate amplicons, as previously suggested [24,25].
One may speculate that secondary rearrangements
may intervene to separate the two genes from the pri-
mary amplicons.
Conclusion
The results of the traditional karyotyping and of FISH
and M-FISH assays on metaphase nuclei reported in this
study highlight that complex structural alterations of
Chr17 encompassing the HER2 gene and CEP17 are
common in breast cancer cell lines. This may reflect the
scenario found in breast carcinomas, as this finding was
also observed in the primary cell culture raised from a
TNBC. Taken together these data indicate that the
HER2/CEP17 ratio of interphase nuclei, routinely used
to select patients for eligibility for anti-HER2 treatment,
should be considered with caution and always coupled
with the HER2 gene copy number values in order not to
misinterpret HER2 gene amplification, as recently up-
dated in the ASCO/CAP 2013 [19].
Further investigation on primary cell cultures would
be of invaluable help to allow functional analysis in cells
harboring Chr17 rearrangements with respect of response
to distinct therapies.
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